Pre-earnings options volume in Crispr Therapeutics is normal with calls leading puts 7:2. Implied volatility suggests the market is anticipating a move near 2.4%, or $1.20, after results are released. Median move over the past eight quarters is 2.7%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- CRISPR Therapeutics to Participate Upcoming Investor Conferences
- Crispr Therapeutics CEO Kulkarni sells $1.3M in company shares
- CRISPR Surges 16% as Cantor Fitzgerald Assigns $72 PT
- CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations